UCB (EBR:UCB) UCB Media Room: Changes on Board of Directors

Transparency directive : regulatory news

15/03/2024 18:00

https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC= rjYrJUHPDVbu1NKaBE-3D65t-_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2= FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN= n-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiUWj1gKfkiKTDVtQHI7i2hy4cIAIvxGs= gaiYY7ZQCG0g9tdsQ6GerkjWJUovC7AiueUlYGTU8bm08Ep1ViSProKYYCn-2F93p3rtKkGjSZf= St8lOg9K6IP8ONWu4nK1ZaocW4rMNDT841PoNED-2Bbr53kTNbemEdzEIE69-2Bh5Mc5aPD-2F0= eSw-2BPKcZID-2BKbUVu22PHRKpY1KicepBuUsO4-3D ** UCB announces changes on Board of Directors ------------------------------------------------------------ Brussels (Belgium), March 15, 2024 =E2=80=936:00 PM (CET)=C2=A0- UCB SA/NV = announces the following changes in the composition of its Board of Director= s.=C2=A0 Fiona du Monceau, currently serving as Vice-Chair of the Board and Chair of= the Governance, Nomination, and Compensation Committee (GNCC), will transi= tion from her position on the Board of Directors to assume an executive rol= e at UCB. We would like to thank Fiona for her contribution to the Board which illust= rated her dedication to people and society, her leadership and strong busin= ess acumen. We warmly anticipate the positive impact she will continue to m= ake in her new capacity. Link to Bio (https://u7061146.ct.sendgrid.net/ls/c= lick?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rC5QjCXs4G-2Boh9iOAc-2BXBqNRCZYI0B-2F6= r-2FWnaXVttpLk-2FYbK2KTucVGv00729NvNOftcb7k2Rn-2FiGGfXXzl7u1ORtqBoAur0nxK7h= 45dnjqQa220uDS5pbk5fxSv-2Bxlz3WgTDiLsTtP9XoKHthfUKmjHOu9zSU2l7HNgCdLnKaAQ8Q= xq3v5fARIra47mbv-2B6An9BJEmjjF-2FKK0BGsWyhEj0Hy5ht30hAEJMT-2FHSYH4JnPdia63X= Ck14GbrzFEzkOwx0epfgSmd-2Buw-2BY-2Bh4GisgjK2MZLLbrLMIBSRhq4qfNs7Y1OneZrzgtV= 6e1H4wTH-2B6rMVI4RUpxt86V3WpNCyMpwKWT2OUmJVtjPJhL31O-2FXO7CTvVDNdZge44-2BSe= Tp5gsAJeTwHG-2FtWs5lXg33Urp-2FjpGXdyaWcn1qd6o05C3-2Bwtqo7POBLllLokHNx4eSAuW= vSkE5aqVavg2Mgd7Nv21q77YMovNcGFhnKTdOOIp1MXExH0AT5c7IyipFQ9soePPhcRg-2BN0oq= RP11wIuc8BZtWTyhaOVjr945qlRrY3ZIwopyZ7GxPxHHz4VeUpwyUoCdbNSuAOoutXp3L5at-2B= EY1nPZL26sOZIeP-2FJwLH11jsX-mpW_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZ= gmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkE= ZvEGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiUWj1gKfkiKTDVtQHI7i2hy4cI= AIvxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovCqxgZcJpJ7iPxpmf5Nm0r5rc4-2BRwUulVSRSaX5s= rP9XAF7UHzohh6uUU9P-2FJsftm8JoWKM8SE5NwWFThn2LFgc6ryaAb-2FYNsZmHqcBgJtqHCNX= ox8WWs9h-2BQgfkdnJmbvvg-2FF-2Fb88md7WPjtCvz3Ks-3D .=C2=A0 We are pleased to announce that Fiona du Monceau will be replaced in her ro= le as Vice-Chair of the Board by Charles-Antoine Janssen already member of = the Board since 2012 and Member of the Audit Committee since 2015 Link to B= io (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuS= ly0rC5QjCXs4G-2Boh9iOAc-2BXBqNRCZYI0B-2F6r-2FWnaXVttpLk-2FYbK2KTucVGv00729N= vNOftcb7k2Rn-2FiGGfXXzl7u1ORtqBoAur0nxK7h45dnjqQa220uDS5pbk5fxSv-2Bxlz3WgTD= iLsTtP9XoKHthfUKmjHoA6hueMbpqxHpo4PAhLba4mPFXM4U4Gg72gTbcBpUAsiLfFaXZdL4-2F= tVf2U9FvqGAmEYcbsP6ViH99sNxz7pAV1ObVM2bZZPMQvIGdeHnsM2EHsvqqZPwJG-2BJVl44qm= Kff7PcGwhnQZYZfL1FQ71TY8S-2BdZDay26I-2B7rgy2r3cS0HOKQg9oMD1D7QfbtfrkilgcY7O= qMc61zwW9X6oU0apEOMqGpNJN2FJjLjdsdl31kwmgBH49pjIUEnQJtefbMFCUcNAXSIe8VoSFmg= iufSqCbFr5-2FvsbLGcU9Ob3SqB5-2BO2DTFvT25zQbwGx2n2Uxt9bmANWgY-2F2r7i9GOgqNaz= Bzon8Lvmm0RWJsXIsCQu3S7GppWDbk7nlqn2eTgycz25U-2FkxiVAqWnBMAcQEhBTuR2oXokUim= nuIpQV-2Bd1osLTKXtTTuB1sLkYaYpZdiVZYiPWUH5-2Fe8GOkfNznNMWPTBNL_2dCLUNbuBjhX= 746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gU= d4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDo= TKRVYiUWj1gKfkiKTDVtQHI7i2hy4cIAIvxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovIv1IBoYHCf= MQ2DliZb-2BW66a4Ossq1Ia8R3TzzqirtWY4hyiUt2yrCM3sf2FaJfX1aVnEJJInfLA-2F9yUxz= iygfN5aIju3jLHy5UIMn-2FUu2gaa10JH8Er56PghGKAdBqlmIM8AxQF9YaNCnsoK5GWdy0-3D = . In accordance with UCB=E2=80=99s Charter of Corporate Governance, the rol= e of Vice-President of the Board is to be attributed to a representative of= the Reference Shareholder. Charles-Antoine will bring forward his long-sta= nding Board experience as well as his breadth of business experience across= the healthcare space. He will also join the Governance, Nomination and Com= pensation Committee and he will be replaced by Cedric van Rijckevorsel as m= ember of the Audit Committee. Link to Bio (https://u7061146.ct.sendgrid.net= /ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rC5QjCXs4G-2Boh9iOAc-2BXBqNRCZYI0= B-2F6r-2FWnaXVttpLk-2FYbK2KTucVGv00729NvNOftcb7k2Rn-2FiGGfXXzl7u1ORtqBoAur0= nxK7h45dnjqQa220uDS5pbk5fxSv-2Bxlz3WgTDiLsTtP9XoKHthfUKmjGP2bbxWvzGjHEa0dCm= gEQt2ufC86qI4QSZyarFc0xQ-2FvbIxcfuBpVy5iknkUWMt5uyJqcjfdfegliLWgvQFzxEEKCtl= 5TZadgVNpYNek3fXzOKyBG0loRSYizFICHFUdUoce42OZ7n2PnRlPTYX5q8wZqGlWOo8xaxwqtA= HQOrbFGkRUhdZc8ZN3bfsgg2gllYcfCGiuzO9vv5cuUU-2BTBF4TSmCNAFjksSghaON27q9Q-2F= PgPGObaJoLfvAN-2B0Ul1NUREA40pfgSLvjXJvFwMFxqG8rDtLpLOEtxP5cXBLAx0-2BAyfxNNM= y8r1Hc7jPUNTP9VpQH1fnQD3zcQDO7Pt0qqDK3DzGQEK-2F07iTnH7n4tbJK-2F-2FZ04RtfnZ-= 2FoQERXPYjW-2BPG6w85TA2GsVFSPHbWiV3S6lFoMCifMpuJ06-2BqlYI8tgWafxQWGRD1epJDP= uSeFlnc5mFV6wZaN4ddkUAt-2BoNFL_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZg= mJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZ= vEGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiUWj1gKfkiKTDVtQHI7i2hy4cIA= IvxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovMt0P3t2J8LvsgMCu78PiI31nIEgZsEEGMXQ88DbodM= yoTsJAXXsulCZflGvMG2tdX-2Bn-2BZeaWLFJUJ-2BU6-2F3zB53THE2VBL05-2BKdlUTrYIH6I= QfVmvu964eQpZejxGTsiF0ve1yMlXlyGkzrODXOjaxQ-3D . Kay Davies, independent member of the Board, will replace Fiona du Monceau = as Chair of the Governance, Nomination and Compensation (GNCC) Committee. K= ay Davies has been a Member of the Board and a Member of the Scientific Com= mittee since 2014. In 2017 she joined as a Member of the GNCC, bringing a r= ich experience to her new role as Chair of this Committee. Link to Bio (htt= ps://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rC5Q= jCXs4G-2Boh9iOAc-2BXBqNRCZYI0B-2F6r-2FWnaXVttpLk-2FYbK2KTucVGv00729NvNOftcb= 7k2Rn-2FiGGfXXzl7u1ORtqBoAur0nxK7h45dnjqQa220uDS5pbk5fxSv-2Bxlz3WgTDiLsTtP9= XoKHthfUKmjEH-2FAVn4OfSU3sjBZ2e542tGIhEwaX8-2BD-2F0YOOWeqDOvMjEdiKjENIfR7eh= FNyN4iZOO96VCpvuS5Y1WZcN0H6ITE-2F30r-2FepQ5Y9987-2BAfFI3-2FfZCz-2FWaNGgXEQL= Q9ndgOUY3GoM0LwfYSgkRyFA1Xn3Y3uJSu1s0Jt-2F5lsjsCQcwYaA-2FB7-2BNNhloMYPX66Rd= MBu00fZDRlaRLVXfXaOnvJmt7MpxhBws4cEPg49ojyKioZQBwdGcJrtX0vP49UlcVQxDGv7hvNr= 5IdKgNWXYVe92ymUqBDBdLSsdXJ1-2BYDPvWojWxTG2HZxrApwGrHXXxEqiDwTBzCVWpZ5yderM= PyIniEnFR4WdPUSfouPK-2F0aPtj8G1-2F1zo5FLFgTqd4epadxgg-2BARJbXon7QnGNdqyO6-2= FAFhTlk0EezfT1P9R-2F26oLYx2p2GSSNFWcft31Ah-2F0-3DVEVx_2dCLUNbuBjhX746-2FvM6= 3L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQ= eFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiUWj= 1gKfkiKTDVtQHI7i2hy4cIAIvxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovOIfjvjcna0JNOexPM2e= 0U8KoY1iqvrGFuJR8mIVduY4j5C-2F3EX26PdK4c66MNbEnzO6gU1Q7-2F-2FE9-2FQ42Q389h6= y4MU9sctKO7lpAeSYKlxF1p0ou7lM0q00Rk1EA2JDkZd-2FhjqTy1eMdkKMOowG2bA-3D . An = amendment to the UCB Charter of Corporate Governance has been decided to al= low an independent Board member to be appointed as Chair of the GNCC. Addit= ionally, Kay Davies will continue to serve as a member of the scientific co= mmittee alongside Susan Gasser and Board nominee Dolca Thomas.=C2=A0 Ulf Wiinberg, independent Member of the Board since 2016, will also join th= e Governance, Nomination and Compensation Committee. Link to Bio (https://u= 7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rC5QjCXs4G= -2Boh9iOAc-2BXBqNRCZYI0B-2F6r-2FWnaXVttpLk-2FYbK2KTucVGv00729NvNOftcb7k2Rn-= 2FiGGfXXzl7u1ORtqBoAur0nxK7h45dnjqQa220uDS5pbk5fxSv-2Bxlz3WgTDiLsTtP9XoKHth= fUKmjEyip2wKaxxifXcyQJgetr-2BfkB96igQYsE3BF4SCwuRhQGem0ZLOQiQhmEvLBBkaVyfJr= UXiopSyMgDkQEYZEiKarhDGzQXpOlILHzHdOXt-2B9K7w2M5v4IRH25j43IkC-2FaPovPMl11li= Zmi3xMbIL2pplWW4MIvzbKVNqYuY5nThXj5QrNn9xBQnHxY-2FR8ie3-2BFfuuCQ1xTPamjGw0H= IRQ7T45-2FGNF0ablW0i7hqN8TRvo8PkpchWED-2BQWSlVTCreFrn2m-2BoVPjOCsTd9gq-2Fo9= yFeqoio1X-2Fdq4hCQJSrV-2FAGbE2PqajRm-2FNI7VXl5rnScSFS-2BOs652xVtI6-2Bhjulqf= 9DTLojzeqfhGV9k6AF2aLej4encylsc-2B3auYtd-2BeF2jouJ-2FelFyYLYAYavBTGxlEtJYAh= Nk1GC-2BYfG6QV4pL7QfMZ1ZsFCjX05i5HzIkVHYDirbsD8PsUprzVt1RzlKo3NRQ_2dCLUNbuB= jhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ= 4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxME= YDoTKRVYiUWj1gKfkiKTDVtQHI7i2hy4cIAIvxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovKEVITQx= BhbHmOWjNhrvVq0QZ8OHMzjgRwiLAznwI-2FD-2FTFTBNNLBwMy3zPmgZn70BjSujkWl4Jc8-2B= qxWifWB7sZN9uQeS0k0v8DXZb8dQ0cczz0CVwTy5wDq1Oq8eHizB-2FQSL38ZRC3WpWvWQP5mmb= 0-3D .=C2=A0 Bert De Graeve, who has been an independent Board Member from 2010 to 2022 = will step down from the Board after the Annual General Meeting of April 25,= 2024, as his successive mandates at UCB exceed 12 years. We would like to = sincerely thank Bert for his exceptional contribution over the years. He ha= s brought deep expertise to the Audit Committee as well a strong independen= t leadership to the Board. Link to Bio (https://u7061146.ct.sendgrid.net/ls= /click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rC5QjCXs4G-2Boh9iOAc-2BXBqNRCZYI0B-2= F6r-2FWnaXVttpLk-2FYbK2KTucVGv00729NvNOftcb7k2Rn-2FiGGfXXzl7u1ORtqBoAur0nxK= 7h45dnjqQa220uDS5pbk5fxSv-2Bxlz3WgTDiLsTtP9XoKHthfUKmjESfn0uKuhBZ8jTIhHVf9R= XaFGDZjEUzVR-2BEURBr8aQx0ZIl2-2Fwm8c0Cs3eEny-2Bh4gGDnc9DDDC596kRT7TTrnEiBtx= xfcOZAD8D4RhtEKUgtFsibuubOCcf3lofJjkaST0Z6-2Fzy24JwcyYu9dKZuA4IqIYl4q0bMnz7= VzCzJn0902FTP-2FGQTlywB1pOLsy-2BrFmv3teVBBexuo-2BaQi0VMmP0sPNSc48kLxcjcGKOY= DGUFxiiSui6Ac1I8aD9ZT9LSEpayg1S0GTuiaP74atNw71p9QZiXJ8QY2S-2Bgsco2Ssan6rYz1= y7SuBJ6Bqwf5xLBehetoaBQ4GyAfTOaaasB4t8MNpCxrYI34mi-2FsZElQ47Qu2CM0h6j5lelh1= u2Cim9XtIvw2qHLMGbiz4Tz0sNKciCipgLTSgEuxPErthPrDSb43EWvLfOutCoK3D7Hmg3Tx-2B= VvkJ9Swtm15X-2FUXU-2BgzRgz-_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl= -2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEG= LNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiUWj1gKfkiKTDVtQHI7i2hy4cIAIvx= GsgaiYY7ZQCG0g9tdsQ6GerkjWJUovNvLzoXc8-2BWyKOFiR0MYV34-2Bb5tbzq8kBTC6dxDC46= W84CxxWuUmATQsdYTFVL856gLZCIkktsycvEzeOjLQAYuVklSIxQG2XC7NPi69IULaUe1jiUrkP= 9qM26jmjQRD01kJezOmplKXfBB0ukNVwo4-3D .=C2=A0 The following Board mandates will be proposed for renewal at the next Annua= l General Meeting of April 25, 2024: =C2=A0 =C2=B7 Renewal of the mandate of Pierre Gurdjian, as independent director, = for a term of 4 years. Pierre Gurdjian will continue to be a Member of the = Governance, Nomination and Compensation Committee. Link to Bio (https://u70= 61146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rC5QjCXs4G-2= Boh9iOAc-2BXBqNRCZYI0B-2F6r-2FWnaXVttpLk-2FYbK2KTucVGv00729NvNOftcb7k2Rn-2F= iGGfXXzl7u1ORtqBoAur0nxK7h45dnjqQa220uDS5pbk5fxSv-2Bxlz3WgTDiLsTtP9XoKHthfU= KmjFNTw2qyfssXLNmu64T3XHLX-2BdUH0BHxJTqBuw1CUQfWXB-2FK-2FpULC4i9Tjg0Heq2wHI= M6I1iYvlI7yNg3Mgd5ovDY009vvQUgqN60G9uVRkx8OEClgimXyNtlV3CK7Cg-2BV-2FsnT-2BH= 5xoQooo9CT1aR3CtanwF8xaTbQP8U2Uf42nAXedxngG2xTarkNywgGxt5oJUM7JqFuMRe1qIIAf= gqvBR-2FGN3R2Cas0ULdLgH3AtvYpKTVVjJLg-2BZlZsLolidk67d23ii3yxGqFLEvAzy-2FHNl= GS4PvSL19wCRtBMygpHURqGnT0-2FwprTIK20Ub1lliPA7PW0SMSn-2BiK7204vT9BhdzPZoZZF= 6K0zsAI3s04hzcPp3sJKEzXPAssxd-2Fws14LS9-2F0LMWhK2WMTIHQ1diO9jHaQW4TmOP1-2Fn= G51lY8qHh1XOSOHplu4WyiI8WAaMsScw35xHvFTicT7Q1xhFby4BBbb_2dCLUNbuBjhX746-2Fv= M63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MT= dQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiU= Wj1gKfkiKTDVtQHI7i2hy4cIAIvxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovEWr7TKAt1ZDhhMzIX= JFZuHRCIUoO5-2BQRuzXFFfTJ0WFAoFDAZR2BxOUXF7H-2FFG1kvVakAIst-2FTQfOf-2BJdyrw= 7LWp8MOxolg-2B8ZkC-2FQlBzJBluPr9YidkvIphR-2Bm1KXgktFojgUw9R0fa-2FdZ5vDQHFM-= 3D .=C2=A0 =C2=B7 Renewal of the mandate of Ulf Wiinberg, as independent director, for= a term of 4 years and as stated above, he will become a Member of the Gove= rnance, Nomination and Compensation Committee. =C2=A0 =C2=B7 Renewal of the mandate of Charles-Antoine Janssen as director, for a= term of 4 years and as stated above, he will become Vice-Chair of the Boar= d and member of the Governance, Nomination and Compensation Committee. =C2= =A0 The Board of Directors also proposes to the UCB Annual General Meeting the = appointment of the following 3 new Board Members: =C2=A0 =C2=B7 Nefertiti Greene, as new independent director, for a term of 4 years= . Link to Bio (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2Ba= xUzlo7XKIuSly0rC5rB1kxObAU1e99kHD7BUidVPSGoTF5FxrwLFsh8z1WJQQLnFaE3Q7cM1NQ5= uL8t7H7oHkjLJtXywQPOupnv6D9XQdVjCv5QdtpTAbnR5ZIIlxUL_2dCLUNbuBjhX746-2FvM63= L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQe= FO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiUWj1= gKfkiKTDVtQHI7i2hy4cIAIvxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovCpfaQSnWDzj2sP9KOSKy= Cl14rrToMTem9vIInNIoAxYTqTGgM6oOZPxsrpi-2B-2F68av3X8nuGRMpDaC1UIulRaHpaVTB4= XI5ubkj7v9V90ok1UrHuD-2Fs12nD0AOt24IPjPmTT6yUyKeTNQwvnAIPLng8-3D . =C2=B7 Dolca Thomas, as new independent director, for a term of 4 years. Li= nk to Bio (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzl= o7XKIuSly0rC5rB1kxObAU1e99kHD7BUidVPSGoTF5FxrwLFsh8z1WJpv9gMTPqKrcf2I9NK-2F= 4GaH87LanaVRNqSQmUe1UotHs-2FVFl85I53YCedBmirmfBTS3A3_2dCLUNbuBjhX746-2FvM63= L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQe= FO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiUWj1= gKfkiKTDVtQHI7i2hy4cIAIvxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovMnnfmbqls067G9KELbjL= mCU-2FUuOJLDnAhFe696U7TAVsqSLgr8k3fJG9Ioy7e8zIsatSSVcEIMyNx29qvu50m-2FJ1FIp= O6CLQt0V4SUO0sDi8iBQjrdCiBP0rQD97vkWa8t8A5CcCYm4FD0PvM8uudI-3D . =C2=B7 Rodolfo Savitzky as new independent director, for a term of 4 years.= Link to Bio (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2Bax= Uzlo7XKIuSly0rC5rB1kxObAU1e99kHD7BUidVPSGoTF5FxrwLFsh8z1WJbB3OzSTaSTM5RBQl4= PcyH1jnlF67TjtVFt5KqRdHF2jAFpVa7yw5PR7OWsHob0FxvPvg_2dCLUNbuBjhX746-2FvM63L= 9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeF= O93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiUWj1g= KfkiKTDVtQHI7i2hy4cIAIvxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovAfOxTE1VXyILNgK0Lz3Nu= Son-2BS8YOTuY7m6MHCwJXg7c5w3Yxa3QVvIjrNyBNxxRXzwxP04XoPrY2lRkuoEp-2FUjaXSI1= mCiLFotFGhyYDbKsl6MWrOM98XXZyjhhtAJWtHruWkMYUFLPgTQUMOPekE-3D . Upon their respective appointment by the UCB Annual General Meeting, Nefert= iti Greene will become a member of the Governance, Nomination and Compensat= ion Committee. Dolca Thomas will become a member of the Scientific Committe= e and Rodolfo Savitzky will become member and Chair of the Audit Committee.= =C2=A0 The UCB Board will continue to be chaired by an independent director, Jonat= han Peacock (link to Bio (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du= 001.gqh-2BaxUzlo7XKIuSly0rC5QjCXs4G-2Boh9iOAc-2BXBqNRCZYI0B-2F6r-2FWnaXVttp= Lk-2FYbK2KTucVGv00729NvNOftcb7k2Rn-2FiGGfXXzl7u1ORtqBoAur0nxK7h45dnjqQa220u= DS5pbk5fxSv-2Bxlz3WgTDiLsTtP9XoKHthfUKmjFBdczZZk4ZVTQ71n70RxsarI4ztUGJfNeKa= fY5vKQLnDq8NDSAHY2e64EQ7r1xZfLWYwJavbdXj3Qnb0qxhP9LJqExdlmDLzoEtfya-2BmNEHZ= dAeR2hq1HLsp556GFju-2FvzN8vxh-2BAJckBYEgZ0Y5WypHT3vjoi6yhiKDxq-2F8GNtnqtdAK= 4wcNo1-2BzqKNfrI4J6QOgCYYlTCa7JRMdgg0eJoTzvHAp1y-2F-2F43Q-2BhfLUZE-2FRZtjKz= yG0Ng1pv3-2F-2ByhcVZ-2FuAu6MK-2BP-2BElymdYEPhGJi2KFWryoueUzVVaJpOAyb9J2uzHy= ABH3HAL-2F-2B85jYFl1RKWwMUCEe7bXR9bYNdx-2B9UrQ3i-2B3yQBqHa34TeJXUOSV28nQGKV= dYHuqfCkoNZkJYamq3maYLuj7Sas16-2B-2FGluep4dK5RKnso6r5ocGh5RBIp69J38kmNEh0Up= RFenKfpddyX8kIaMoBXraesi7PqfE_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgm= Jl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZv= EGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiUWj1gKfkiKTDVtQHI7i2hy4cIAI= vxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovO-2F5LtbnzXC7ZtTueulkVnzH3BKS3R7p30R7MrgXe8= E3TYNEqTlN2oKj-2F5vB7skjtNOpSeex4iGyDdpk429dxSo0QzRYyQ-2F4v1iLNf881YzD-2F-2= F5v4fZOkWd0r6rHJsfwiRHkjil7PXmkW212yXt4sHs-3D ). If the above 3 proposed re= newals and appointments are approved by our Annual General Meeting of April= 25, 2024, the Board will continue to be composed of a majority of independ= ent directors (10 out of 14 members) and the Audit Committee and the Govern= ance, Nomination and Compensation Committee will be chaired by independent = directors, respectively Kay Davies and Rodolfo Savitzky. From a gender dive= rsity perspective, the Board will be composed of 6 women and 8 men. "I am thrilled with the recent updates to our Board, which reflect the cont= inued strong support from our reference shareholder and highlight our commi= tment to diversity and broad experience among our independent board members= ," stated Jonathan Peacock, UCB's Chair of the Board. "With a clear focus o= n innovation and growth, UCB is well-positioned to maintain its growth traj= ectory, backed by a robust Board committed to putting patients at the heart= of everything we do." For further information, contact UCB:=C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 9 000 peopl= e in approximately 40 countries, the company generated revenue of =E2=82=AC= 5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Fol= low us on Twitter: @UCB_news Forward looking statements=C2=A0 This press release contains forward-looking statements, including, without = limitation, statements containing the words =E2=80=9Cpotential=E2=80=9D, = =E2=80=9Cbelieves=E2=80=9D, =E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects= =E2=80=9D, =E2=80=9Cintends=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Csee= ks=E2=80=9D, =E2=80=9Cestimates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cw= ill=E2=80=9D, =E2=80=9Ccontinue=E2=80=9D and similar expressions. These for= ward-looking statements are based on current plans, estimates and beliefs o= f management. All statements, other than statements of historical facts, ar= e statements that could be deemed forward-looking statements, including est= imates of revenues, operating margins, capital expenditures, cash, other fi= nancial information, expected legal, arbitration, political, regulatory or = clinical results or practices and other such estimates and results. By thei= r nature, such forward-looking statements are not guaranteeing future perfo= rmance and are subject to known and unknown risks, uncertainties, and assum= ptions which might cause the actual results, financial condition, performan= ce or achievements of UCB, or industry results, to be materially different = from any future results, performance, or achievements expressed or implied = by such forward-looking statements contained in this press release.=C2=A0 Important factors that could result in such differences include but are not= limited to: global spread and impacts of wars and pandemics, changes in ge= neral economic, business and competitive conditions, the inability to obtai= n necessary regulatory approvals or to obtain them on acceptable terms or w= ithin expected timing, costs associated with research and development, chan= ges in the prospects for products in the pipeline or under development by U= CB, effects of future judicial decisions or governmental investigations, sa= fety, quality, data integrity or manufacturing issues; potential or actual = data security and data privacy breaches, or disruptions of our information = technology systems, product liability claims, challenges to patent protecti= on for products or product candidates, competition from other products incl= uding biosimilars, changes in laws or regulations, exchange rate fluctuatio= ns, changes or uncertainties in tax laws or the administration of such laws= , and hiring and retention of its employees. There is no guarantee that new= product candidates will be discovered or identified in the pipeline, or th= at new indications for existing products will be developed and approved. Mo= vement from concept to commercial product is uncertain; preclinical results= do not guarantee safety and efficacy of product candidates in humans. So f= ar, the complexity of the human body cannot be reproduced in computer model= s, cell culture systems or animal models. The length of the timing to compl= ete clinical trials and to get regulatory approval for product marketing ha= s varied in the past and UCB expects similar unpredictability going forward= . Products or potential products which are the subject of partnerships, joi= nt ventures or licensing collaborations may be subject to disputes between = the partners or may prove to be not as safe, effective or commercially succ= essful as UCB may have believed at the start of such partnership. UCB=E2=80= =99s efforts to acquire other products or companies and to integrate the op= erations of such acquired companies may not be as successful as UCB may hav= e believed at the moment of acquisition. Also, UCB or others could discover= safety, side effects or manufacturing problems with its products and/or de= vices after they are marketed. The discovery of significant problems with a= product similar to one of UCB=E2=80=99s products that implicate an entire = class of products may have a material adverse effect on sales of the entire= class of affected products. Moreover, sales may be impacted by internation= al and domestic trends toward managed care and health care cost containment= , including pricing pressure, political and public scrutiny, customer and p= rescriber patterns or practices, and the reimbursement policies imposed by = third-party payers as well as legislation affecting biopharmaceutical prici= ng and reimbursement activities and outcomes. Finally, a breakdown, cyberat= tack or information security breach could compromise the confidentiality, i= ntegrity and availability of UCB=E2=80=99s data and systems. Given these uncertainties, you are cautioned not to place any undue relianc= e on such forward-looking statements. These forward-looking statements are = made only as of the date of this press release, and do not reflect any pote= ntial impacts from the evolving conflicts, wars, pandemics, as well as any = other adversity, unless indicated otherwise. The company continues to follo= w the development diligently to assess the financial significance of these = events, as the case may be, to UCB. UCB expressly disclaims any obligation or duty to update any forward-lookin= g statements in this press release, either to confirm the actual results or= to report or reflect any change in its forward-looking statements with reg= ard thereto or any change in events, conditions or circumstances on which a= ny such statement is based, unless such statement is required pursuant to a= pplicable laws and regulations. GenericFile UCB PR Board changes March 15 2024 ENG (https://u7061146.ct.sendgrid.net/ls= /click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepZPTecmgsJkq= Gk95GRgq9YNgQfNg-2FMXKnHLJ1-2Bd2TteW46szUTv15r6AAEYRTLVMgQ-3DD9O__2dCLUNbuB= jhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ= 4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxME= YDoTKRVYiUWj1gKfkiKTDVtQHI7i2hy4cIAIvxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovJsbWkWz= oRoffFp2HUZsHUQwIHnIISjPF78hhf5LpsNX6fbE3KB2opuFARCUkftnptqO8rCBUa3qAdqdy46= mn13Q0VKrX5fIcDJvpz8F4fM2Sy8TqLI8MYLICoOKSdyG9BjPQyrxMo4TRaHKBmjjmPY-3D ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu= Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNI9w8zt5unRMkpysg750Tb9Pp= eZbJfNzTy-2FMbzu9IYaQwnf2YX4XiZX-2FUO7aHu9MkQi-2F6qLfsJyRcDImpbYSX-2BDo-2B9= nJ2JqvaCJLI1-2FnWQ-2BQ-3D33Me_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgm= Jl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZv= EGLNn-2B6FohpNoV33yU-2BZBlc-2BQzYQusxMEYDoTKRVYiUWj1gKfkiKTDVtQHI7i2hy4cIAI= vxGsgaiYY7ZQCG0g9tdsQ6GerkjWJUovOFzAof4oWwVbB21NpAByfpse8sdLsMLrPfqEnssOACk= nV4Xij993Q3-2FvxYFtwl5E2UBIFYbOezqBgvXLUSuq5yHbT8Ky7buf-2BJgaITRhbJq9BMfm06= 7iHi6DgJiMS9LyB-2B7KqWy3iiO-2BoLLcUakAHo-3D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium

UCB's latest news

25/04/2024 18:00

UCB (EBR:UCB) UCB Media Room: Changes on Board of Directors

Transparency directive : regulatory news

UCB's latest news

Other stories